InsidersTradesSigma
Follow the Adverum Biotechnologies, Inc. share price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Adverum Biotechnologies, Inc. has recorded 60 public disclosures. The latest transaction was filed on 10 December 2025 (U). Among the most active insiders: Leonard Braden Michael. All data is accessible without an account.
60
Insider Decl.
n/a
Thresholds
€4m
22 ops.
Buy Volume
€3m
16 ops.
Sell Volume
38Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 10 December 2025
Declarations60 total
54,874 sharesCommon StockSEC:0001903088-25-000005:0
8,125 sharesCommon Stock - Restricted Stock UnitsSEC:0001814883-25-000005:0
13,000 sharesCommon StockSEC:0001775323-25-000004:0
80,189 sharesCommon StockSEC:0001736315-25-000006:0
5,000 sharesCommon StockSEC:0001574579-25-000004:0
150,000 shares@ US$4.2075.8% of flowCommon StockSEC:0001379344-25-000006:0
10,333 sharesCommon StockSEC:0001356950-25-000004:0
48,750 shares@ US$4.2056.4% of flowCommon StockSEC:0001321937-25-000005:0
8,818 sharesCommon StockSEC:0001311210-25-000004:0
4,288,949 shares@ US$3.56100.0% of flowCommon StockSEC:0001231919-25-000588:0
50,000 shares@ US$4.2271.6% of flowCommon StockSEC:0001736315-25-000004:0
Canonical exit: 5 Mar 2026 (T+90)
11,085 shares@ US$4.245.7% of flowCommon StockSEC:0001379344-25-000004:0
Canonical exit: 5 Mar 2026 (T+90)
524,560 shares@ US$4.194729.6% of flowCommon StockSEC:0001373604-25-000122:0
300,000 shares@ US$4.2017.1% of flowCommon StockSEC:0001373604-25-000118:0
2,960 shares@ US$2.004.6% of flowCommon StockSEC:0001415889-25-013446:0
9,126 shares@ US$2.0010.9% of flowCommon StockSEC:0001415889-25-013442:0
924 shares@ US$2.005.1% of flowCommon StockSEC:0001415889-25-013444:0
20,407 shares@ US$5.03952.8% of flowCommon StockSEC:0001373604-25-000069:0
Canonical exit: 24 Jun 2025 (T+90)
20,407 shares@ US$5.03952.8% of flowCommon StockSEC:0001373604-25-000067:0
Canonical exit: 24 Jun 2025 (T+90)
300,000 shares@ US$3.0023.4% of flowCommon StockSEC:0001373604-25-000065:0
Canonical exit: 21 Jul 2025 (T+90)
19,566 shares@ US$4.37842.3% of flowCommon StockSEC:0001373604-25-000058:0
Canonical exit: 29 Jun 2025 (T+90)
20,407 shares@ US$5.03952.8% of flowCommon StockSEC:0001373604-25-000056:0
Canonical exit: 24 Jun 2025 (T+90)
18,000 shares@ US$4.602.2% of flowCommon StockSEC:0001373604-25-000051:0
Canonical exit: 16 Jun 2025 (T+90)
164,886 shares@ US$4.008718.5% of flowCommon StockSEC:0001373604-25-000041:0
Canonical exit: 27 May 2025 (T+90)
25,000 shares0Common StockSEC:0001415889-25-005833:0
25 of 60 declarations
关于 Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc. 是一家临床阶段的生物制药公司，在美国纳斯达克市场上市。该公司专注于眼科基因疗法，其战略核心是针对普遍存在的、造成大量未满足医疗需求的眼部疾病。Adverum 成立于 2006 年，总部位于加利福尼亚州红木城，地处旧金山湾区生物技术集群。其公司定位围绕着基因疗法可能成为威胁视力的视网膜疾病新护理标准的理念。（[adverum.com](https://adverum.com/wp-content/uploads/Adverum-Corporate-Overview_2025.pdf?utm_source=openai)) Adverum 的商业模式本质上是管线驱动的。该公司的专有玻璃体内平台旨在通过医生诊室环境提供持久疗法，旨在减轻目前视网膜护理中常见的频繁重复注射的负担。其主要资产是 ixoberogene soroparvovec，或 Ixo-vec（前身为 ADVM-022），这是一种一次性玻璃体内基因疗法候选药物，正在开发用于新生血管性或湿性年龄相关性黄斑变性（湿性 AMD）。管理层已将 Ixo-vec 定位为一种潜在的长效疗法，旨在提供持续的阿柏西普表达并减少与标准抗 VEGF 方案相关的治疗负担。（[adverum.com](https://adverum.com/about-us/?utm_source=openai)) 从竞争角度来看，Adverum 在一个拥挤且快速发展的视网膜治疗领域运营。标准护理抗 VEGF 注射仍然是湿性 AMD 的商业基准，而多家生物技术公司正在寻求更长效的替代方案，包括基因疗法方法和其他持续递送技术。Adverum 的差异化在于其“一劳永逸”的雄心：如果成功，它可以提供注射自由和与慢性给药截然不同的价值主张。与此同时，这是一个高风险领域，因为临床疗效、安全性、持久性和监管接受度都是关键的门槛因素。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1393434/000155837025002000/ocul-20241231x10k.htm?utm_source=openai)) 近期公司里程碑事件非常重要。2025 年，Adverum 启动了 ARTEMIS，这是其 Ixo-vec 的首次关键性 3 期试验，此前报告的 2 期和长期随访数据显示该公司支持该项目的潜力。2025 年 10 月，Adverum 和礼来公司宣布了一项交易，礼来公司同意收购 Adverum，为投资案例增加了重要的战略维度。因此，对于投资者而言，ADVM 应被视为一个在纳斯达克上市的美国生物技术故事，具有二元临床上行空间、专注的眼科基因疗法管线以及活跃的并购叠加。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1501756/000162828025017769/exhibit991_41525pressrelea.htm?utm_source=openai))
